Objective: To characterize non-motor symptoms in individuals with Parkinson’s disease (PD) who experience falls compared to those who do not fall. Methods: Fifty-four individuals with PD were studied. Thirty-six were fallers and 18 were non-fallers. Fatigue was assessed by the Iowa Fatigue Scale. Excessive daytime sleepiness was assessed by the Epworth Sleepiness Scale, and depressive symptomatology was assessed by the short-form Center for Epidemiologic Studies Depression Scale. Results: Compared to non-fallers, fallers had more severe disability, greater general physical fatigue (p = 0.024), lower energy levels (p = 0.042) and less productivity (p = 0.007). Fallers had more depressive symptomatology than the non-fallers (p = 0.01). Excessive daytime sleepiness was not different between the two groups (p = 0.695). Conclusions: Individuals with PD who fell had more severe motor and non-motor symptoms than those who did not fall. These non-motor symptoms included physical fatigue, energy, productivity and depressive symptomatology.

1.
Bulpitt CJ, Shaw K, Clifton P, Stern G, Davies JB, Reid JL: The symptoms of patients treated for Parkinson’s disease. Clin Neuropharmacol 1985;8:175–183.
2.
Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464–474.
3.
Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology: Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924–931.
4.
Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG: Depression in Parkinson’s disease. J Nerv Ment Dis 1990;178:27–31.
5.
Partinen M: Sleep disorder related to Parkinson’s disease: J Neurol 1997;244(4 suppl 1):S3–S6.
6.
Beiske AG, Loge JH, Hjermstad MJ, Svensson E: Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord 2010;25:2456–2460.
7.
Herlofson K, Larsen JP: The influence of fatigue on health-related quality of life in patients with Parkinson’s disease. Acta Neurol Scand 2003;107:1–6.
8.
Herlofson K, Larsen JP: Measuring fatigue in patients with Parkinson’s disease – the Fatigue Severity Scale. Eur J Neurol 2002;9:595–600.
9.
Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J: Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001;57:1392–1396.
10.
Schrag A: Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006;248:151–157.
11.
Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E: Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology 2010;21:658–668.
12.
Koller WC, Glatt S, Vetere-Overfield B, Hassanein R: Falls and Parkinson’s disease. Clin Neuropharmacol 1989;12:98–105.
13.
Ashburn A, Stack E, Pickering RM, Ward CD: A community-dwelling sample of people with Parkinson’s disease: characteristics of fallers and non-fallers. Age Ageing 2001;30:47–52.
14.
Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P; Chinese Parkinson Study Group: Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 2009;15:767–771.
15.
Martinez-Martin P: The importance of non-motor disturbances to quality of life in Parkinson’s disease. J Neurol Sci 2011;310:12–16.
16.
Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, Ruessmann A, Odin P, Macphee G, Stocchi F, Ondo W, Sethi K, Schapira AH, Martinez Castrillo JC, Martinez-Martin P: The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010;25:704–709.
17.
Miwa H, Miwa T: Fatigue in patients with Parkinson’s disease: impact on quality of life. Intern Med 2011;50:1553–1558.
18.
Knie B, Mitra MT, Logishetty K, Chaudhuri KR: Excessive daytime sleepiness in patients with Parkinson’s disease. CNS Drugs 2011;25:203–212.
19.
Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson’s disease rating scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson’s Disease. Florham Park, Macmillan Health Care Information, 1987, vol 2.
20.
Hoehn M, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427–442.
21.
Oehlert ME, Hass SD, Freeman MR, Williams MD, Ryan JJ, Sumerall SW: The Neurobehavioral Cognitive Status Examination: accuracy of the ‘screen-metric’ approach in a clinical sample. J Clin Psychol 1997;53:733–737.
22.
Camicioli R, Majumdar SR: Relationship between mild cognitive impairment and falls in older people with and without Parkinson’s disease: 1-Year Prospective Cohort Study. Gait Posture 2010;32:87–91.
23.
Hartz A, Bentler S, Watson D: Measuring fatigue severity in primary care patients. J Psychosom Res 2003;54:515–521.
24.
Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–545.
25.
Johns MW: Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15:376–381.
26.
Radloff LS: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401.
27.
Andresen EM, Malmgren JA, Carter WB, Patrick DL: Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 1994;10:77–84.
28.
Irwin M, Artin KH, Oxman MN: Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D). Arch Intern Med 1999;159:1701–1704.
29.
Bass C: Fatigue states. Br J Hosp Med 1989;41:315.
30.
Beiske AG, Svensson E: Fatigue in Parkinson’s disease: a short update. Acta Neurol Scand Suppl 2010;190:78–81.
31.
Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR: Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol 2010;17:1428–1436.
32.
Castillo PR: Uncovering sleepiness versus fatigue in Parkinson disease. Eur J Neurol 2010;17:1407.
33.
Thannickal TC, Lai YY, Siegel JM: Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson’s disease. Brain 2008;131:e87.
34.
Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME: Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005;17:310–323.
35.
Wood BH, Bilclough JA, Bowron A, Walker RW: Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry 2002;72:721–725.
36.
Robinson K, Dennison A, Roalf D, Noorigian J, Cianci H, Bunting-Perry L, Moberg P, Kleiner-Fisman G, Martine R, Duda J, Jaggi J, Stern M: Falling risk factors in Parkinson’s disease. NeuroRehabilitation 2005;20:169–182.
37.
Simuni T, Sethi K: Nonmotor manifestations of Parkinson’s disease. Ann Neurol 2008;64(suppl 2):S65–S80.
38.
Brown AS, Gershon S: Dopamine and depression. J Neural Transm Gen Sect 1993;91:75–109.
39.
Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ: Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord 2009;15:110–115.
40.
van Iersel MB, Verbeek AL, Bloem BR, Munneke M, Esselink RA, Rikkert MG: Frail elderly patients with dementia go too fast. J Neurol Neurosurg Psychiatry 2006;77:874–876.
41.
Yogev-Seligmann G, Hausdorff JM, Giladi N: The role of executive function and attention in gait. Mov Disord 2008;23:329–342.
42.
Allcock LM, Ullyart K, Kenny RA, Burn DJ: Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:1470–1471.
43.
Bassetti CL: Nonmotor disturbances in Parkinson’s disease. Neurodegener Dis 2011;8:95–108.
44.
Gray P, Hildebrand K: Fall risk factors in Parkinson’s disease. J Neurosci Nurs 2000;32:222–228.
45.
Martignoni E, Tassorelli C, Nappi G: Cardiovascular dysautonomia as a cause of falls in Parkinson’s disease. Parkinsonism Relat Disord 2006;12:195–204.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.